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DNAAbstract Background: For children with cancer, the clinical integration of precision medi-
cine to enable predictive biomarkerebased therapeutic stratification is urgently needed.
Methods: We have developed a hybrid-capture next-generation sequencing (NGS) panel, spe-
cifically designed to detect genetic alterations in paediatric solid tumours, which gives reliable
results from as little as 50 ng of DNA extracted from formalin-fixed paraffin-embedded
(FFPE) tissue. In this study, we offered an NGS panel, with clinical reporting via a molecular
tumour board for children with solid tumours. Furthermore, for a cohort of 12 patients, we
used a circulating tumour DNA (ctDNA)especific panel to sequence ctDNA from matched
plasma samples and compared plasma and tumour findings.
Results: A total of 255 samples were submitted from 223 patients for the NGS panel. Using
FFPE tissue, 82% of all submitted samples passed quality control for clinical reporting. At
least one genetic alteration was detected in 70% of sequenced samples. The overall detection
rate of clinically actionable alterations, defined by modified OncoKB criteria, for all sequenced
samples was 51%. A total of 8 patients were sequenced at different stages of treatment. In 6 of
these, there were differences in the genetic alterations detected between time points.
Sequencing of matched ctDNA in a cohort of extracranial paediatric solid tumours also iden-
tified a high detection rate of somatic alterations in plasma.
Conclusion: We demonstrate that tailored clinical molecular profiling of both tumour DNA
and plasma-derived ctDNA is feasible for children with solid tumours. Furthermore, we show
that a targeted NGS panelebased approach can identify actionable genetic alterations in a
high proportion of patients.
Crown Copyright ª 2019 Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In adult malignancies, precision medicine initiatives
enabling standardised, high-throughput molecular
profiling and predictive biomarkerebased stratification
have been implemented to maximise clinical efficacy of
targeted therapeutics [1e7]. Similar initiatives are ur-
gently needed for childhood cancer, which remains the
primary cause of death in children after infancy [8].
In children, comprehensive molecular profiling pro-
grammes have incorporated whole-exome sequencing
(WES) and RNA sequencing (RNA-seq) and, in some
cases, copy number analysis, whole-genome sequencing
(WGS), microarray or methylation arrays. Such initia-
tives have detected potentially actionable findings in
46e60.9% of patients [9e11]. However, logistical and
financial practicalities limit large-scale implementation of
this approach in most health-care settings. Targeted next-
generation sequencing (NGS) panels are typically more
cost-effective and can be tailored to the study
population and standardised according to regulatory re-
quirements. Therefore, this may present a more suitable
alternative for implementation into health-care systems.Generic adult cancer gene panels have been used in
children [12,13]; however, the spectrum of mutations
differs between adult and paediatric tumours. For
example, recurrent H3 mutations are a hallmark of
paediatric high-grade glioma [14,15], and rearrange-
ments upstream to the TERT promoter are frequent in
neuroblastoma [16]. These differences necessitate a
tailored approach to determine common and actionable
events; hence, we have developed and clinically vali-
dated a paediatric-specific solid tumour NGS panel for
use in precision medicine [17].
In children with relapsed/refractory cancer, access to
adequate biopsy material remains challenging [18,19].
Therefore, our strategy has been to optimise the paedi-
atric panel for use on formalin-fixed paraffin-embedded
(FFPE) tissue if frozen tissue is unavailable and, in
parallel, begin evaluating more-easily accessible sources
of tumour DNA, such as plasma.
Plasma-derived circulating tumour DNA (ctDNA)
has been shown to be an alternative to repeat biopsy in
common adult malignancies [20e23]. ctDNA analysis is
minimally invasive, amenable to serial sampling and
may also give more representative information
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in children with cancer have detected somatic mutations
in small volumes of plasma [26e30].
Here, we report the development of version 2 of our
paediatric solid tumourespecific NGS panel and the na-
tional implementation of clinical NGS panel sequencing.
We report on assay performance and the clinical relevance
of the findings. In parallel, we evaluate the feasibility of
performing targeted sequencing of ctDNA in a clinical
laboratory setting using a ctDNA-specific NGS panel.2. Materials and methods
2.1. Patients
A Royal Marsden Hospital (RM) pilot study for patients
aged 24 years with solid tumours treated at our Children
and Young People’s Unit commenced in March 2016 and
was subsequently expanded nationally for children aged
16 years. Ethical approval was obtained from the Na-
tional Research Ethics Service (reference: 15/LO/07) and
the Biological Studies Steering Group of the Children’s
Cancer and Leukaemia Group (reference: 2015 BS 09).
Participants and/or guardians gave informed consent. Pa-
tients were eligible to enrol at any time including diagnosis
and relapse/progression. Blood was taken for germline
DNA analysis, and archival tissue was retrieved from the
most recent surgery, or if indicated, a repeat biopsy could
be requested at the treating clinician’s discretion.2.2. Sample preparation and sequencing
Sample preparation, DNA extraction, library prepara-
tion and sequencing were performed according to
established protocols [17,31]. Two different panels were
used: version 1 (v1, 78 genes, 311 kb) and version 2 (v2,
91 genes, 473 kb) (Table S1). The custom hybridisation
panel is capable of detecting single-nucleotide variants
(SNVs), small insertions and deletions (indels), copy
number variations (CNVs) and structural variants for
which we capture the region where the breakpoint oc-
curs, for instance, 50 kb upstream to the TERT pro-
moter [16]. Sequencing output files were processed as
previously reported [31]. Only somatic variants, detected
after subtraction of germline findings, were reported.
Samples were analysed initially using MiSeq Reporter
version 2.5 (http://emea.support.illumina.com/sequencing/
sequencing_software/miseq_reporter/downloads.html).
Analysis was later executed using an in-house devel-
oped pipeline Molecular Diagnostic Information
Management System version 3.0 (MDIMSv3) using the
following bioinformatic software and versions: demul-
tiplexing was performed using bcl2fastq 2.17.1.14,
reads were aligned using BWA 0.7.12, structural vari-
ants were identified using Manta 0.29.6, SNVs and
indels were called with GATK 3.5.0 and variants wereannotated with Oncotator version 1.5.1.0. CNVs were
assessed as previously described [17].2.3. Gene panel capture version 2, design and validation
Integral to the study design was the ability to update
and adapt the regions included on the panel according
to clinical need and target prioritisation. For v2, genes
were ranked by consensus expert opinion according to
set selection criteria (Table S1). The panel was validated
using four cell blends (Tru-Q1-4 Horizon Discovery,
Cambridge, United Kingdom [UK]) and 10 FFPE
samples with known variants (SNVs Z 554,
indels Z 79). Quality and coverage metrics were calcu-
lated across all the samples including (i) total reads, (ii)
percentage of reads mapped to the reference sequence,
(iii) percentage of duplicates, (iv) percentage of bases
from unique reads deduplicated on target and (v) mean
depth. Sensitivity, specificity and accuracy were deter-
mined by comparing the cell blends and FFPE samples
with known variants and known true negatives.2.4. Molecular tumour board
A monthly molecular tumour board (MTB) was estab-
lished for discussion of findings, and the interpreted re-
sults were then reported to the treating clinician. The
MTB core members included paediatric/adolescent
oncologists, experts in early clinical trials, molecular
pathologists, bioinformaticians and paediatric tumour
biologists, from the RM, Great Ormond Street Hospital
and The Institute of Cancer Research, London. OncoKB
was used as a basis to define tiers of actionability [32]. In
addition, COSMIC [33]-defined mutations/SNVs, genetic
amplifications, gains or losses, for which a paediatric
clinical trial was currently recruiting, were also consid-
ered, as well as alterations where compelling preclinical
paediatric data existed for that target (Table S1). Het-
erozygous gene loss and missense mutations outside of
defined hotspot regions were defined as not actionable.2.5. ctDNA extraction and analysis
A total of 12 plasma samples were identified for
sequencing where the corresponding tumour samples
contained at least one genetic alteration present on the
ctDNA panel. The plasma ctDNA sequencing results
were not reported back to the MTB.
About 5 to 10 mL of blood was collected into cell-free
DNA blood collection tubes (Streck, La Vista, United
States of America) and centrifuged twice at 1600 g.
ctDNA extraction and sequencing using a commercially
available hybrid-capture panel (Avenio ctDNA
expanded kit, Roche) was performed according to the
manufacturer’s instructions.
Fig. 1. Study overview. After obtaining informed consent, tumour and blood samples were collected. DNA was extracted, and sequence li-
braries were prepared using the capture-based paediatric solid tumour panel. After sequencing, samples underwent an in-house data analysis
pipeline thatdetectsmutations, structural variants and copynumber changes.Genomicalterationsweremanually reviewedby two independent
scientists and then discussed in a molecular tumour board before a clinical report was issued. FFPE, formalin-fixed paraffin-embedded.
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3.1. Version 2 of the paediatric solid tumour panel
v1 of the panel was validated as previously reported [17].
v2 was also validated to Good Laboratory and Clinical
Practice standards and performed well, comparable withv1, obtaining a similar number of reads and percentage
of unique on-target reads (Figure S1A-C). The poly-
merase chain reaction (PCR) duplicate percentage was
improved (v1 Z 55.3% and v2 Z 20.3%) (Figure S1D).
The sensitivity for detection of SNVs was 99% and
90% for indels at 5% variant allele frequency (VAF)
(Table S2). The specificity for SNVs was 98% at 5%
Fig. 2. Tumour samples submitted for sequencing. Summary of sample flow and the total number of samples successfully sequenced (A).
Distribution of tumour types among reported cases (B). DSRCT, desmoplastic small round cell tumour; CNS, central nervous system.
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and indels between droplet digital polymerase chain
reaction (ddPCR) and v2 was 0.9527 (Figure S1E) and
between v1 and v2 was 0.9301 (Figure S1F).3.2. Patient samples and overall performance
An overview of the study is given in Fig. 1. A total of
255 samples were submitted from 223 patients.
Although patients were eligible to enrol at any time,
90% of evaluable patients had at least one episode of
progression/relapse before study enrolment. FFPE tis-
sue from the most recent surgery was requested for all
but 3 patients where fresh frozen tissue was used.
Adequate coverage for clinical reporting of results
was obtained in 82% of submitted samples (Fig. 2A).
Reasons for sample rejection or failure were as follows:
tumour content less than 10%, DNA less than 20 ng
and/or excessive DNA fragmentation. The median
depth of coverage for all reported samples was 495
(interquartile range: 264e868). The most common can-
cers sequenced were glioma (38), neuroblastoma (27)
and rhabdomyosarcoma (26) (Fig. 2B).3.3. Genetic findings
At least one genetic alteration was detected in 70% (145/
209) of samples at an allele frequency  5%. The so-
matic genetic alterations detected, grouped according to
underlying diagnosis, are summarised in Fig. 3, Table S3
and Fig S2. In keeping with other studies [34], the most
frequently mutated gene was TP53 in 36/209 (17%); in
addition high frequencies of alterations in genes known
to be recurrently altered in paediatric malignancies such
as ATRX, CDKN2A, CTNNB1 in 12/209 (5.7%),
MYCN in 11/209 (5.2%) and H3F3A, PIK3CA in 10/209
(4.3%) were detected.
3.4. Clinical actionability
Potentially targetable alterations, defined byOncoKB tiers
of actionability in addition to predictive biomarkers for
currently recruiting paediatric clinical trials, were detected
in 51% of sequenced samples (Fig. 4A). Of the 107 tumour
samples classified as potentially actionable, 42 (39%) had
greater than one actionable alteration detected. For each
tumour sample, only the alteration for which there was the
highest tier of evidence for actionability was included.
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alterations found, followed by osteosarcoma and rhab-
domyosarcoma (Fig. 4B). No tier 1 alterations (US Food
and Drug Administration [FDA]erecognised biomarker
predictive of response to an FDA-approved drug) were
detected, indicative of the lack of regulatory approvals for
paediatric indications. Only one patient had a tier 2A
alteration: a patient with an inflammatorymyofibroblastic
tumour, harbouring anALK:SQSTM1 translocation. The
patient had a complete surgical resection and did not
require systemic therapy.
As a feasibility study, follow-up data were not
routinely collected for all patients. Of the 57 patients
with a tier 2B or 3 alteration and available follow-up
data, only four (7%) received targeted therapies:
Three patients with BRAFV600E mutations were
treated with dabrafenib/trametinib combination therapy:
patient 1 had a pleomorphic xanthoastrocytoma and was
commenced on dabrafenib/trametinib after third disease
progression. The patient remains on treatment with sta-
ble disease after 9 months. Patient 2 had glioblastoma
multiforme and was commenced on dabrafenib/trameti-
nib after disease progression. The patient had stable
disease for 13 months before further progression. Patient
3 had multiply relapsed metastatic ameloblastic fibro-
odontosarcoma [35]; by day 28 of treatment, there had
been a partial response but asymptomatic cardiac
toxicity, required discontinuation of both drugs. On
normalisation of the shortening and ejection fractions,
the patient was recommenced on single-agent dabrafenib
and had sustained partial response for 15 further months.
A patient with multiply relapsed metastatic germinoma
and PDGFRA/KIT amplification was given dasatinib,
but progressed on treatment.
One patient with high-grade glioma (patient ID 045-
T) had a total of 49 somatic mutations (Table S3) (in
w0.18 Mb) consistent with a hypermutator phenotype,
associated with mismatch repair deficiency and predic-
tive of potential sensitivity to immune checkpoint
blockade [36]. However, the patient was not fit for
clinical trial enrolment by the time the sequencing re-
sults were available.
Other patients had findings that informed prognosis:
a mutation in CTNNB1 was found in a patient originally
diagnosed with supratentorial primitive neuro-
ectodermal tumour (PNET), biologically more in keep-
ing with a WNT-activated medulloblastoma. Other
examples included an MYOD1 mutation in a patient
with embryonal rhabdomyosarcoma, associated with
distinct clinical features and poor prognosis [37], and a
RELA-c11orf95 fusion in a patient with supratentorial
ependymoma, associated with high-risk disease [38].
3.5. Analysis of paired samples
For eight patients, paired samples were sequenced at
different stages of treatment (Fig. 5). In six of these,there were differences between the variants detected at
different time points. Mutations in PTEN, NF1 and
TP53 were observed in a patient with high-grade glioma
(patient 2) after dabrafenib/trametinib treatment but not
in the pre-treatment sample. The patient subsequently
received everolimus but progressed after 3 months on
treatment. The acquisition of NF1 mutations as a
resistance mechanism after BRAF inhibition is consis-
tent with findings in BRAFV600E-mutant melanoma
[39,40]. in another child with glioma sequenced at
diagnosis and progression, the tumour harboured
shared alterations in H3F3A and TP53, whereas PTEN
was only present at diagnosis and PIK3CA at progres-
sion. In a patient with Wilms tumour, a potentially
targetable TSC2 mutation was found in the 3rd relapse
sample, which was not present in the previous sample.3.6. ctDNA analysis
ctDNA was sequenced in a cohort of 12 patients with
extracranial tumours, in whom the tumour panel had
detected a genetic alteration that was also covered by a
commercially available ctDNA sequencing panel. In 3
patients, in whom ctDNA and FFPE were sequenced
from the same time point, there was a direct concor-
dance between findings. However, in 5 patients, from
whom plasma was collected after at least one subsequent
relapse, variants were detected in the plasma that were
not detected in FFPE samples (Table 1). For example, in
a patient with neuroblastoma, an ALK F1174L muta-
tion was detected in both tumour and plasma; however,
an additional ALK hotspot mutation was also detected
in the plasma that was not present in the tumour sample.
In addition, of note, in 2 cases, variants detected in
plasma at relapse were only identified at very low levels
in diagnostic tumour samples, below the predefined limit
of detection for clinical reporting.4. Discussion
Comprehensive molecular profiling strategies have been
shown to be feasible in children with cancer [9e11] and
show encouraging results. However, wide-scale imple-
mentation is impractical in most health-care settings,
and even if resources were unlimited, it is also restricted
by the availability of biopsy material. We show that
using as little as 50 ng of DNA, this assay is an accurate,
reproducible and practical platform for molecular
stratification and identification of actionable targets,
required to accelerate precision medicine clinical trials in
childhood tumours.
We are aware that although capture-based panel
sequencing is an excellent tool, it has limitations. With
our targeted panel approach, only a small portion of the
genome is sequenced, and therefore, it is not always
possible to distinguish between focal gains or deletions
S.L. George et al. / European Journal of Cancer 121 (2019) 224e235230
Table 1
Results of ctDNA panel sequencing of matched plasma samples and comparison with tumour panel sequencing for genes covered by both panels,


























Neuroblastoma 5 5th relapse 5th relapse 18.54 TP53 C135F 74.0% 20.30% 13348 393
Wilms tumour 19 Post induction Post
induction
32.22 TP53 G245D 77.0% 7.44% 5498 402
Ewing sarcoma 84 2nd relapse 2nd relapse 50 TP53 C176Y 87.0% 49.90% 3453 70
Neuroblastoma 214 Diagnosis 2nd relapse 7.5 ALK R1275Q N/D 3.11%c 2954 528
ALK F1174L 17.0% 3.88% 2242 354
APC R499* 0.24%a 0.31% 2580 412
Ewing sarcoma 315 Diagnosis Relapse 34.02 TP53 R273C 48.0%b N/D 3557 314
TP53 R337C N/D 31.40%c 5237 391






51.96 CTNNB1 S33Pro 33.00%b N/D 5194 777
RMS 444 Diagnosis 2nd relapse 18.6 TP53 V173M F 11.43% 2782 17
PIK3CA E542K 15.0%b N/D 2166 167
PIK3CA E545K 17.0% 0.56%a 2065 180
Osteosarcoma 514 Diagnosis 2nd relapse 33.96 TP53 R248T 78.0% 11.08% 6334 91
TP53 Y220C N/D 0.29%c 5510 542
Neuroblastoma 738 Post induction 1st relapse 168.6 TP53 R249S N/D 0.05%c 14825 193
ALK D1091N 8.0% 0.03% 22632 308
RMS 954 Diagnosis 2nd relapse 29.52 KRAS G12C 92.0% 0.09%a 3233 1453
Wilms tumour 1211 Diagnosis 3rd relapse 50.76 TP53 R273C 100.0% 23.96% 3961 74
Wilms tumour 1322 Post induction 3rd relapse 19.86 TP53 R181C 86.0% 3.72% 2525 141
TP53 C176Y N/D 3.03%c 2439 174
FFPE, formalin-fixed paraffin-embedded; ctDNA, circulating tumour DNA; RMS, rhabdomyosarcoma; ACC, adrenocortical carcinoma; VGPR,
very good partial response, postinduction, surgical resection after routine induction chemotherapy, AF, allele fraction; F, failed coverage; N/D, not
detected.
a Below limit of detection.
b Detected in tumour only.
c Detected in plasma only.
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version 3 of the panel, we are incorporating a new assay
to determine this, which includes probes located across
the chromosomes. In addition, as novel gene discoveries
and/or targeted inhibitors become available, a wider
approach is required for certain indications including a
more extensive method for detection of structural vari-
ants/translocations. Capture NGS panels are able to
detect translocations in DNA with the ability to deter-
mine the single-nucleotide breakpoint, so long as those
breakpoints occur in or close to a targeted region. We
used MANTA to detect spanning pair reads and split
reads, thereby identifying fusion gene partners. However,
detection of fusion genes is inevitably restricted. We are
therefore currently validating a panel using anchored
multiplex PCR-based enrichment to detect fusions fromFig. 3. Overview of sequencing results. Oncoprint represents somatic m
that are covered by the targeted panel. Samples are grouped in column
to the tumour type and genes sorted by frequency. Panel version, samp
according to the included key (A). Bar plot of most recurrent altered ge
type (B). FFPE, formalin-fixed paraffin-embedded; DSRCT, desmopl
fresh frozen.RNA, removing the need to sequence long and complex
intronic regions. Furthermore, methylation profiling is
particularly relevant for precise diagnostic classification
of central nervous system (CNS) tumours, many of which
harbour few if any recurrent somatic alterations.
Therefore, in the Stratified Medicine Paediatrics
(SMPaeds) national molecular profiling study for chil-
dren with relapsed and refractory cancers, we will retain
the practical advantages of panel sequencing and run
this alongside other more comprehensive profiling mo-
dalities including WES, RNA-seq, low-coverage WGS
and methylation to support biomarker-driven clinical
trials in the UK, such as eSMART [41]. Furthermore,
where sufficient tissue is available, concurrent analysis
via the National Health Service England WGS pro-
gramme will be compared with SMPaeds genomic andutations and gains, amplification and deletions detected in genes
s with genes displayed along rows. Samples are arranged according
le type, molecular annotations and diagnosis are provided as bars
nes, sorted by frequency and colour coded according to the tumour
astic small round cell tumour; CNS, central nervous system; FF,
Fig. 4. Clinical actionability. Somatic alterations were defined according to OncoKB levels of evidence. Actionability tiers are described in
the key. Distribution of actionability tiers for the entire sequenced cohort (A). Distribution of actionability tiers across common tumours,
colour coded according to the tumour type (B). DSRCT, desmoplastic small round cell tumour; CNS, central nervous system.
S.L. George et al. / European Journal of Cancer 121 (2019) 224e235232clinical data. This approach will provide an unbiased
assessment of the clinical utility and cost-effectiveness of
multiple different modalities to enable formal recom-
mendations for implementation into routine molecular
diagnostics.
Despite the high detection rate of potentially
actionable alterations, few patients received treatment
with targeted agents. The reasons for this were multi-
factorial and include the following: lack of available
clinical trials, difficulties accessing novel drugs on a
compassionate-use basis and/or clinical deterioration ofthe patient. In addition, although many patients had
relapsed/refractory disease, a considerable proportion
of patients were still on either first-line therapy or
proven standard relapse therapies at the time of
sequencing. A number of patients were also enrolled in
available phase I/II trials that did not require
biomarker screening.
This was a pilot study, requiring retrieval of archival
tissue, batching of samples for sequencing and infre-
quent MTBs. However, for the prospective SMPaeds
study, which mandates biopsy at relapse for molecular
Fig. 5. Comparison of results from paired samples, sequenced at different time points. Venn diagrams compare the genetic findings in eight
patients. Shared alterations are illustrated by the intersection of the two ovals. Alterations detected at only the 1st time point are rep-
resented in the pink oval, and alterations identified at the 2nd time point only are represented in the green oval. The size of the oval
represents the number of variants identified in each patient.
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in a clinically relevant time frame, which after clinical
feedback is currently 3e4 weeks, with the final goal of
returning data in two weeks. For children with primary
solid tumours (who are not enrolled in SMPaeds), as a
result of this study, NGS panel sequencing on the
paediatric solid tumour panel v2 is now offered in the
UK as part of routine National Health Service diag-
nostic testing with a turnaround time of 4 weeks from
sample dispatch to reporting. Owing to ethical and
consent constraints, we were not permitted to report
germline findings in the present study. However, given
the obvious clinical importance of predisposing muta-
tions in paediatric cancer, we have now obtained suit-
able consents to report germline mutations via an
accredited genetics clinic at Great Ormond Street
Hospital.
The sequencing of paired tumour samples at different
times demonstrates the importance of tumour hetero-
geneity and evolution, adding to the mounting literature
in support of the clinical importance of biopsy at relapse
for children with cancer [19,42]. Notably, many tumour
mutations emerging at the time of relapse (PTEN, NF1,
PIK3CA and TSC2) are recognised predictive bio-
markers of a targeted therapeutic response.Although sequencing tissue samples of patients is
crucial, liquid biopsies offer the possibility of a non-
invasive source for tumour genotyping and disease
monitoring. Our preliminary findings from a small
number of children demonstrate that high-depth
sequencing of ctDNA can identify actionable somatic
variants. We also identified some discrepancies between
tumour and plasma, most likely a reflection of tumour
heterogeneity and evolution. However, large-scale vali-
dation studies comparing tumour and serial ctDNA
findings in children with cancer are needed to define the
clinical utility of ctDNA analysis, for which a bespoke
ctDNA panel for paediatric solid tumours is currently
being developed to be incorporated as part of the di-
agnostics pipeline.
In summary, we demonstrate the value of targeted
gene sequencing as a practical and cost-effective clinical
tool to enable improved diagnosis, prognostication and
therapeutic stratification for children with cancer.Acknowledgements
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